Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fendrix versus double-dose Engerix in HIV-infected hepatitis B vaccine non-responders
NL-OMON36269Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of Hepatitis B vaccine and hepatitis B vaccine recombinant in hepatitis B (HBV) (2 arms), sponsored by Erasmus MC. Primary endpoint: Anti-HBs titer at week 28. Started Mar 2011; status: active, not recruiting.
02
Drugs
Hepatitis B vaccinehepatitis B vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NL-OMON36269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36269.